A Universal MicroCT Analysis Pipeline for Bone Preclinical Disease Models
Getting a good microCT image of your animal’s bone, in vivo or ex vivo, is just the start. To realize the goals of your preclinical study, quantitative outcomes are needed. From two decades of experience, Bruker microCT brings a universal microCT analysis pipeline – a transparent flexible system and workflow that can deliver your needed quantitative outcomes, for every disease model.
With some systems on the market, each individual disease model and analysis requires a new software module or attachment and big new software bill! Not so with Bruker CT-Analyzer and CT-Voxel. This powerful yet intuitive system builds on a simple pipeline to deliver results for any bone analysis scenario.
Phil Salmon, PhD - Application Scientist, Bruker microCT
What is this pipeline?
- Think about what you want to find out. Plan the in-vivo study and imaging method accordingly. Run a pilot study first if necessary. Does the method resolve what you need to see?
- Scan bone sites in-vivo or ex-vivo by microCT for 3D morphometry and/or densitometry
- Align the 3D image for consistent and optimal selection of a region of interest for analysis
- Region of interest: setting this is the key to equivalence between animals and power and accuracy in the resulting data
- Segmentation: apply an suitable binary threshold for bone or other tissues or biomaterials to be analyzed
- 3D analysis and interpretation of the morphometric and/or densitometric data.
This pipeline is easy to learn and can be applied to models of osteoporosis, arthritis, bone tumor and metastasis, fracture callus, defect healing with biomaterials, articular cartilage deficit, genetic phenotypes and even others yet to be developed (or to be developed by you).
Who should attend
- Researchers in bone biology and orthopedics, including osteoporosis, arthritis, bone tumor, biomaterials, fracture healing and any other bone related discipline.
- Research technicians involved in imaging and image analysis.
- Pharmaceutical decision makers involved in planning discovery and screening programs related to bone health.
- Scientists involved in microCT imaging and quantitative image analysis.